SNS-032 decreases active HSCs to alleviate hepatic fibrosis by inducing the apoptosis of active HSCs and inhibiting their activation and proliferation by inhibiting the expression of CDK9 and blocking the phosphorylation of RNAP II and its downstream factors (Figure 7). Here, CDK9 is linked to Hepatic fibrosis.